{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T13:59:55Z","timestamp":1778162395064,"version":"3.51.4"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T00:00:00Z","timestamp":1578528000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.yebeh.2019.106864","type":"journal-article","created":{"date-parts":[[2020,1,11]],"date-time":"2020-01-11T22:52:20Z","timestamp":1578783140000},"page":"106864","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"PA","title":["Safety and tolerability of adjunctive brivaracetam in epilepsy: In-depth pooled analysis"],"prefix":"10.1016","volume":"103","author":[{"given":"Christian","family":"Brandt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavel","family":"Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Badalamenti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Gasalla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Whitesides","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2019.106864_bb0005","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejphar.2011.04.064","article-title":"Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties","volume":"664","author":"Gillard","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.yebeh.2019.106864_bb0010","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/epi.12432","article-title":"Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial","volume":"55","author":"Ryvlin","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.106864_bb0015","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/epi.12433","article-title":"Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial","volume":"55","author":"Biton","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.106864_bb0020","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1111\/epi.13212","article-title":"A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures","volume":"56","author":"Klein","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.106864_bb0025","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1212\/WNL.0000000000002864","article-title":"Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies","volume":"87","author":"Ben-Menachem","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2019.106864_bb0030","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1212\/WNL.0b013e3181ec7f7f","article-title":"Adjunctive brivaracetam for refractory partial-onset seizures: a randomized, controlled trial","volume":"75","author":"French","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2019.106864_bb0035","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1528-1167.2012.03598.x","article-title":"Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trial","volume":"54","author":"Van Paesschen","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.106864_bb0040","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/epi.12391","article-title":"Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial","volume":"55","author":"Kwan","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.106864_bb0045","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/epi.13433","article-title":"Bioavailability and bioequivalence comparison of brivaracetam 10, 50, 75, and 100\u202fmg tablets and 100\u202fmg intravenous bolus","volume":"57","author":"Stockis","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.106864_bb0050","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1111\/epi.13409","article-title":"Safety and tolerability of adjunctive brivaracetam as intravenous infusion or bolus in patients with epilepsy","volume":"57","author":"Klein","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.106864_bb0055","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.eplepsyres.2016.08.018","article-title":"Tolerability, safety, and efficacy of adjunctive brivaracetam for focal seizures in older patients: A pooled analysis from three phase III studies","volume":"127","author":"Brodie","year":"2016","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2019.106864_bb0060","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.yebeh.2006.08.008","article-title":"Psychiatric and behavioral side effects of the newer antiepileptic drugs in adults with epilepsy","volume":"10","author":"Weintraub","year":"2007","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2019.106864_bb0065","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1111\/j.1528-1167.2007.01262.x","article-title":"Are psychiatric adverse events of antiepileptic drugs a unique entity? A study on topiramate and levetiracetam","volume":"48","author":"Mula","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.106864_bb0070","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1093\/brain\/aww196","article-title":"Psychotic disorders induced by antiepileptic drugs in people with epilepsy","volume":"139","author":"Chen","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.yebeh.2019.106864_bb0075","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1111\/epi.13416","article-title":"Safety, tolerability, and seizure control during long-term treatment with adjunctive brivaracetam for partial-onset seizures","volume":"57","author":"Toledo","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.106864_bb0080","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/epi.13638","article-title":"Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein","volume":"58","author":"Wood","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.106864_bb0085","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/epi.13340","article-title":"Brivaracetam: rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment","volume":"57","author":"Klitgaard","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.106864_bb0090","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0920-1211(01)00296-0","article-title":"A systematic review of the safety profile of levetiracetam: a new antiepileptic drug","volume":"47","author":"French","year":"2001","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2019.106864_bb0095","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1528-1157.2000.tb04605.x","article-title":"Efficacy and tolerability of levetiracetam 3000\u202fmg\/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy","volume":"41","author":"Ben-Menachem","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.106864_bb0100","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1528-1157.2000.tb00323.x","article-title":"Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures","volume":"41","author":"Shorvon","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.106864_bb0105","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1212\/WNL.55.2.236","article-title":"Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial","volume":"55","author":"Cereghino","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2019.106864_bb0110","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.yebeh.2015.09.005","article-title":"An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam","volume":"52","author":"Yates","year":"2015","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2019.106864_bb0115","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1111\/epi.13768","article-title":"Postmarketing experience with brivaracetam in the treatment of epilepsies: A multicenter cohort study from Germany","volume":"58","author":"Steinig","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.106864_bb0120","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.seizure.2017.03.010","article-title":"Real-life experience with brivaracetam in 101 patients with difficult-to-treat epilepsy\u2014a monocenter survey","volume":"48","author":"Steinhoff","year":"2017","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2019.106864_bb0125","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s10072-014-1701-0","article-title":"Anticonvulsant drugs and hematological disease","volume":"35","author":"Verrotti","year":"2014","journal-title":"Neurol Sci"},{"key":"10.1016\/j.yebeh.2019.106864_bb0130","author":"UCB Inc"},{"key":"10.1016\/j.yebeh.2019.106864_bb0135","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.seizure.2007.10.007","article-title":"Levetiracetam-associated hyponatremia","volume":"17","author":"Belcastro","year":"2008","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2019.106864_bb0140","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1185\/03007990802278453","article-title":"Effect of brivaracetam on cardiac repolarisation\u2014a thorough QT study","volume":"24","author":"Rosillon","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.yebeh.2019.106864_bb0145","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.iac.2014.04.005","article-title":"Hypersensitivity to antiepileptic drugs","volume":"34","author":"Ye","year":"2014","journal-title":"Immunol Allergy Clin N Am"},{"key":"10.1016\/j.yebeh.2019.106864_bb0150","author":"UCB Inc"},{"key":"10.1016\/j.yebeh.2019.106864_bb0155","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/sj.clpt.6100492","article-title":"Assessing abuse liability during drug development: changing standards and expectations","volume":"83","author":"Schoedel","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.yebeh.2019.106864_bb0160","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.yebeh.2017.09.008","article-title":"Human abuse potential of brivaracetam in healthy recreational central nervous system depressant users","volume":"78","author":"Schoedel","year":"2018","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2019.106864_bb0165","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/j.1365-2125.2006.02829.x","article-title":"The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males","volume":"63","author":"Sargentini-Maier","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.yebeh.2019.106864_bb0170","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2125.2008.03158.x","article-title":"The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men","volume":"66","author":"Rolan","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.yebeh.2019.106864_bb0175","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S1474-4422(11)70193-4","article-title":"Risk of sudden unexpected death in epilepsy in patients given adjunctive antiepileptic treatment for refractory seizures: a meta-analysis of placebo-controlled randomised trials","volume":"10","author":"Ryvlin","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2019.106864_bb0180","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S1474-4422(16)30158-2","article-title":"Sudden unexpected death in epilepsy: epidemiology, mechanisms, and prevention","volume":"15","author":"Devinsky","year":"2016","journal-title":"Lancet Neurol"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505019308224?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505019308224?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:30:37Z","timestamp":1761503437000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505019308224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":36,"alternative-id":["S1525505019308224"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2019.106864","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and tolerability of adjunctive brivaracetam in epilepsy: In-depth pooled analysis","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2019.106864","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"106864"}}